Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update

Area of Science:

• Virology
• Drug Discovery
• Biochemistry

Background:

• Viral DNA integration into host chromosomes is essential for the viral life cycle, mediated by viral integrase (IN).
• Integrase is a validated drug target due to its unique enzymatic activity, essential role in replication, and lack of cellular homologues.
• Existing integrase inhibitors, like S-1360, show synergistic effects with other antiviral drugs, highlighting the potential of this drug class.

Purpose of the Study:

• To review small molecule compounds reported to inhibit recombinant HIV-1 integrase (IN) with IC(50) values < 20 µM.
• To identify and categorize emerging classes of IN inhibitors based on recent literature.
• To assess the potential of these compounds as novel antiviral agents.

Main Methods:

• Literature review of studies published within the past two years reporting on small molecule inhibitors of HIV-1 IN.
• Analysis of reported IC(50) values to identify potent inhibitors (< 20 µM).
• Categorization of inhibitors based on chemical structure, focusing on catechol and diketoacid containing compounds.

Main Results:

• Numerous small molecule compounds inhibiting HIV-1 IN have been identified in the last two years.
• Predominant inhibitor classes include catechol-containing hydroxylated aromatics and diketoacid-containing aromatics.
• The precise mechanism of action and antiviral activity for many newly identified compounds remain to be fully established.

Conclusions:

• Small molecule inhibitors targeting viral integrase are a growing area of antiviral research.
• While many compounds show potent inhibition of recombinant HIV-1 IN, further studies are needed to establish their mechanism of action and in vivo efficacy.
• Certain classes of compounds can be excluded as genuine IN inhibitors based on current literature, aiding future drug development efforts.